

|                               |                           |                  |
|-------------------------------|---------------------------|------------------|
| <b>Notice of Allowability</b> | Application No.           | Applicant(s)     |
|                               | 10/534,295                | CHANG ET AL.     |
|                               | Examiner<br>Ruth A. Davis | Art Unit<br>1651 |

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address--

All claims being allowable, PROSECUTION ON THE MERITS IS (OR REMAINS) CLOSED in this application. If not included herewith (or previously mailed), a Notice of Allowance (PTOL-85) or other appropriate communication will be mailed in due course. **THIS NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RIGHTS**. This application is subject to withdrawal from issue at the initiative of the Office or upon petition by the applicant. See 37 CFR 1.313 and MPEP 1308.

1.  This communication is responsive to amendment and response filed 9/17/2007.
2.  The allowed claim(s) is/are 8-9.
3.  Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
  - a)  All
  - b)  Some\*
  - c)  None
 of the:
  1.  Certified copies of the priority documents have been received.
  2.  Certified copies of the priority documents have been received in Application No. \_\_\_\_\_.
  3.  Copies of the certified copies of the priority documents have been received in this national stage application from the International Bureau (PCT Rule 17.2(a)).

\* Certified copies not received: \_\_\_\_\_.

Applicant has THREE MONTHS FROM THE "MAILING DATE" of this communication to file a reply complying with the requirements noted below. Failure to timely comply will result in ABANDONMENT of this application.  
**THIS THREE-MONTH PERIOD IS NOT EXTENDABLE.**

4.  A SUBSTITUTE OATH OR DECLARATION must be submitted. Note the attached EXAMINER'S AMENDMENT or NOTICE OF INFORMAL PATENT APPLICATION (PTO-152) which gives reason(s) why the oath or declaration is deficient.
5.  CORRECTED DRAWINGS ( as "replacement sheets") must be submitted.
  - (a)  including changes required by the Notice of Draftsperson's Patent Drawing Review ( PTO-948) attached
    - 1)  hereto or 2)  to Paper No./Mail Date \_\_\_\_\_.
  - (b)  including changes required by the attached Examiner's Amendment / Comment or in the Office action of Paper No./Mail Date \_\_\_\_\_.

Identifying indicia such as the application number (see 37 CFR 1.84(c)) should be written on the drawings in the front (not the back) of each sheet. Replacement sheet(s) should be labeled as such in the header according to 37 CFR 1.121(d).
6.  DEPOSIT OF and/or INFORMATION about the deposit of BIOLOGICAL MATERIAL must be submitted. Note the attached Examiner's comment regarding REQUIREMENT FOR THE DEPOSIT OF BIOLOGICAL MATERIAL.

#### Attachment(s)

1.  Notice of References Cited (PTO-892)
2.  Notice of Draftsperson's Patent Drawing Review (PTO-948)
3.  Information Disclosure Statements (PTO/SB/08),  
Paper No./Mail Date \_\_\_\_\_
4.  Examiner's Comment Regarding Requirement for Deposit  
of Biological Material
5.  Notice of Informal Patent Application
6.  Interview Summary (PTO-413),  
Paper No./Mail Date \_\_\_\_\_
7.  Examiner's Amendment/Comment
8.  Examiner's Statement of Reasons for Allowance
9.  Other \_\_\_\_\_.

/Ruth A. Davis/  
Primary Examiner  
Art Unit: 1651

Attorney Docket No.: DC-0315  
Inventors: Chang and Sugii  
Serial No.: 10/534,295  
Filing Date: June 9, 2005  
Page 2

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claims 1-7 (canceled).

1 Claim 8 (currently amended): A method of inhibiting over accumulation of cholesterol intracellularly in cells comprising administering to the cells a cholesterol inhibitor identified by the a method of claim 2 comprising exposing mutant NPC1 cells to a test agent, permeabilizing the mutant NPC1 cells, evaluating the intracellular level of cholesterol accumulation in the permeabilized mutant NPC1 cells exposed to the test agent via binding of labeled C theta complex to cholesterol-rich domains in intracellular organelles, and comparing the evaluated level to the intracellular level of cholesterol bound to labeled C theta complex in mutant NPC1 cells not exposed to the test agent, wherein a decrease in the level of cholesterol accumulation intracellularly in the mutant NPC1 cells exposed to the test agent as compared to the intracellular level in mutant NPC1 cells not exposed to the test agent is indicative of the test agent being a cholesterol inhibitor.

2 Claim 8 (currently amended): A method of inhibiting over accumulation of cholesterol intracellularly in cells comprising administering to the cells a cholesterol inhibitor identified by the a method of claim 5 comprising exposing mutant NPC1 cells to a test agent, permeabilizing the mutant NPC1 cells, evaluating

Attorney Docket No.: **DC-0315**  
Inventors: **Chang and Sugii**  
Serial No.: **10/534,295**  
Filing Date: **June 9, 2005**  
Page 3

the intracellular level of cholesterol accumulation in the permeabilized mutant NPC1 cells exposed to the test agent via binding of labeled C theta complex to cholesterol-rich domains in intracellular organelles, and comparing the evaluated level to the intracellular level of cholesterol bound to labeled C theta complex in parental cells not exposed to the test agent, wherein the intracellular level of cholesterol accumulation in the mutant NPC1 cells exposed to the test agent is equal to the intracellular level of cholesterol in the parental cells not exposed to the test agent is indicative of the test agent being a cholesterol inhibitor.

Claims 10-11 (canceled).